• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Final report of the OLYMPUS Jelmyto trial: Takeaways for urologists


“I think that these data firmly establish UGN-101, or Jelmyto, as a bona fide treatment option for kidney preservation for patients with low-grade, non-invasive urothelial cancer in the upper urinary tract,” says Seth P. Lerner, MD.

In this video, Seth P. Lerner, MD, gives the final results of the phase 3 OLYMPUS trial, which studied the efficacy of mitomycin-containing reverse thermal gel (UGN-101; Jelmyto) in patients with upper tract urothelial carcinoma and supported the FDA approval of the treatment in this setting.

Lerner is a professor in the Scott Department of Urology and Beth and Dave Swalm Chair in urologic oncology at the Baylor College of Medicine Medical Center in Houston, Texas.

Related Videos
Mature woman with her doctor | Image Credit: © pucko_ns - stock.adobe.com
Gary D. Steinberg, MD, an expert on bladder cancer
Jaleh Fallah, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.